Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2020 May 24

PMID 32443860

Citations 11

Authors

Thuy Trang Nguyen

Qui Thanh Hoai Ta

Thi Kim Oanh Nguyen

Thi Thuy Dung Nguyen

Van Giau Vo

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a complex neurodegenerative disease that requires extremely specific biomarkers for its diagnosis. For current diagnostics capable of identifying AD, the development and validation of early stage biomarkers is a top research priority. Body-fluid biomarkers might closely reflect synaptic dysfunction in the brain and, thereby, could contribute to improving diagnostic accuracy and monitoring disease progression, and serve as markers for assessing the response to disease-modifying therapies at early onset. Here, we highlight current advances in the research on the capabilities of body-fluid biomarkers and their role in AD pathology. Then, we describe and discuss current applications of the potential biomarkers in clinical diagnostics in AD.

Citing Articles

Using cerebrospinal fluid biomarkers to diagnose Alzheimer's disease: an Australian perspective.

Eratne D, Collins S, Nestor P, Pond D, Velakoulis D, Yates M Front Psychiatry. 2024; 15:1488494.

PMID: 39703457 PMC: 11656523. DOI: 10.3389/fpsyt.2024.1488494.

AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring.

Wasilewski T, Kamysz W, Gebicki J Biosensors (Basel). 2024; 14(7).

PMID: 39056632 PMC: 11274923. DOI: 10.3390/bios14070356.

Natural flavonoids as potential therapeutics in the management of Alzheimer's disease: a review.

Nguyen-Thi P, Vo T, Pham T, Nguyen T, Van Vo G 3 Biotech. 2024; 14(3):68.

PMID: 38357675 PMC: 10861420. DOI: 10.1007/s13205-024-03925-8.

Alzheimer's Disease: Significant Benefit from the Yeast-Based Models.

Epremyan K, Mamaev D, Zvyagilskaya R Int J Mol Sci. 2023; 24(12).

PMID: 37372938 PMC: 10298092. DOI: 10.3390/ijms24129791.

Altered Mitochondrial Morphology and Bioenergetics in a New Yeast Model Expressing Aβ42.

Epremyan K, Rogov A, Goleva T, Lavrushkina S, Zinovkin R, Zvyagilskaya R Int J Mol Sci. 2023; 24(2).

PMID: 36674415 PMC: 9862424. DOI: 10.3390/ijms24020900.

References

Martorana A, Di Lorenzo F, Belli L, Sancesario G, Toniolo S, Sallustio F . Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State. CNS Neurosci Ther. 2015; 21(12):921-5. PMC: 6493161. DOI: 10.1111/cns.12476. View

Bereczki E, Branca R, Francis P, Pereira J, Baek J, Hortobagyi T . Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain. 2018; 141(2):582-595. PMC: 5837272. DOI: 10.1093/brain/awx352. View

Hampel H, Buerger K, Zinkowski R, Teipel S, Goernitz A, Andreasen N . Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004; 61(1):95-102. DOI: 10.1001/archpsyc.61.1.95. View

Pais M, Martinez L, Ribeiro O, Loureiro J, Fernandez R, Valiengo L . Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Braz J Psychiatry. 2020; 42(4):431-441. PMC: 7430379. DOI: 10.1590/1516-4446-2019-0735. View

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

Lauridsen C, Sando S, Moller I, Berge G, Pomary P, Grontvedt G . Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42. Front Aging Neurosci. 2017; 9:210. PMC: 5487529. DOI: 10.3389/fnagi.2017.00210. View

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky S . The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimers Res Ther. 2020; 12(1):21. PMC: 7053087. DOI: 10.1186/s13195-020-00588-4. View

Zetterberg H . Blood-based biomarkers for Alzheimer's disease-An update. J Neurosci Methods. 2018; 319:2-6. DOI: 10.1016/j.jneumeth.2018.10.025. View

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

10.

Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J . Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2014; 24(1):1-10. PMC: 5588216. DOI: 10.1159/000369101. View

11.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

12.

Sjogren M, Gisslen M, Vanmechelen E, Blennow K . Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett. 2001; 314(1-2):33-6. DOI: 10.1016/s0304-3940(01)02285-6. View

13.

Buerger K, Teipel S, Zinkowski R, Blennow K, Arai H, Engel R . CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002; 59(4):627-9. DOI: 10.1212/wnl.59.4.627. View

14.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

15.

Bateman R, Barthelemy N, Horie K . Another step forward in blood-based diagnostics for Alzheimer's disease. Nat Med. 2020; 26(3):314-316. DOI: 10.1038/s41591-020-0797-4. View

16.

Nabers A, Perna L, Lange J, Mons U, Schartner J, Guldenhaupt J . Amyloid blood biomarker detects Alzheimer's disease. EMBO Mol Med. 2018; 10(5). PMC: 5938617. DOI: 10.15252/emmm.201708763. View

17.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

18.

Foster E, Dangla-Valls A, Lovestone S, Ribe E, Buckley N . Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci. 2019; 13:164. PMC: 6403191. DOI: 10.3389/fnins.2019.00164. View

19.

Frost S, Martins R, Kanagasingam Y . Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis. 2010; 22(1):1-16. DOI: 10.3233/JAD-2010-100819. View

20.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View